Solid Biosciences Inc
solidbio.comWhat Do They Do?
Develops gene therapy candidates for patients with rare neuromuscular and cardiac diseases, including Duchenne muscular dystrophy, Friedreich’s ataxia and inherited heart conditions.
10-K for FY2025, filed Mar 19, 2026
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 6, 2026
−$54.8MView ↗
- ▲ +39% (Loss)
- vs −$39.5M in Q2 FY2025
-
Aug 6, 2026
Opens a new stock offering of up to $200.0 million
The company filed a prospectus supplement for sales under its sales agreement, after selling approximately $85.0 million under the prior supplement.
Sources
8-K, filed Aug 6, 2026
On August 6, 2026, Solid Biosciences Inc. (the “Company”) filed a prospectus supplement (the “Prospectus Supplement”) under the Company’s…View ↗
Who Do They Compete With?
Competes with Sarepta Therapeutics, Genethon, REGENXBIO, Insmed, Nippon Shinyaku, Avidity Biosciences, Wave Life Sciences, Dyne Therapeutics, BioMarin Pharmaceutical, Entrada Therapeutics, Italfarmaco, Edgewise Therapeutics, Capricor Therapeutics, Satellos Bioscience, Precision BioSciences, Lexeo Therapeutics, Neurocrine Biosciences, Voyager Therapeutics, Capsida Biotherapeutics, and Design Therapeutics
10-K for FY2025, filed Mar 19, 2026We are aware of a number of companies and research institutions developing gene transfer programs progressing in Duchenne. For example, in…View ↗
Loading...
